Department of Diagnostic Radiology, Molecular Imaging and Therapy Section, Oregon Health & Sciences University, Portland, OR, USA.
Department of Diagnostic Radiology, Medical Physics Section, Oregon Health & Sciences University, Portland, OR, USA.
Curr Probl Cancer. 2024 Oct;52:101129. doi: 10.1016/j.currproblcancer.2024.101129. Epub 2024 Sep 3.
Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
生长抑素受体（SSTR）靶向成像和治疗分化良好的神经内分泌肿瘤（NETs）的进展彻底改变了这些肿瘤的治疗方式。这篇全面的综述深入探讨了目前的实践，讨论了各种 FDA 批准的 SSTR 激动剂 PET 示踪剂和预测性成像生物标志物的应用，并详细阐述了 Lu177-DOTATATE 肽受体放射性核素治疗（PRRT），包括治疗后成像实践、PRRT 再治疗以及剂量学在优化患者治疗中的潜在作用等不断发展的领域。未来方向部分强调了正在进行的研究，包括研究性 PET 成像放射性示踪剂、α粒子治疗的未来前景以及联合治疗策略。
